The EPO’s May 2020 decision in G3/19, on the patentability of certain plants, was among the most controversial in the office’s history. Anna Gregson of Mathys & Squire explores the implications.
- Analysis: Kymab’s ‘patent bargain’ clarification and why it matters 25-06-2020
- SPCs: a deep dive into CJEU case law 23-06-2020
- Will the EU’s SPC manufacturing waiver weaken European pharma’s IP? 20-05-2020
- Royalty Pharma: welcome clarity mixed with unwelcome ambiguity 15-05-2020
- Why things could get ugly over COVID-19 patents 30-04-2020
Latest europe news
Drug company Teva has lost an appeal over its bid to trademark two word signs, after the tenth chamber of the EU General Court ruled in favour of the European Union IP Office (EUIPO) yesterday, July 8.